Murray J. Towle

Eisai (United States) — United States

Medicine · Health Sciences

19h-index1.9kcitations41works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(20), HER2/EGFR in Cancer Research(11), Microbial Natural Products and Biosynthesis(9), Microtubule and mitosis dynamics(7), Marine Sponges and Natural Products(7)

Publications41 total

Supplementary Data from Potent <i>in vitro</i> and <i>in vivo</i> anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A
2023Open Access
Data from Potent <i>in vitro</i> and <i>in vivo</i> anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A
2023Open Access
Data from Potent <i>in vitro</i> and <i>in vivo</i> anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A
2023Open Access
Supplementary Data from Potent <i>in vitro</i> and <i>in vivo</i> anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A
2023Open Access
Data from Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for <i>In vivo</i> Efficacy under Intermittent Dosing Conditions
2023Open Access
Supplementary Figures 1-2 from Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
2023Open Access
Data from Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for <i>In vivo</i> Efficacy under Intermittent Dosing Conditions
2023Open Access
Supplementary Figure Legends 1-2 from Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
2023Open Access
Supplementary Figures S1-S4 from Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for <i>In vivo</i> Efficacy under Intermittent Dosing Conditions
2023Open Access
Supplementary Figures S1-S4 from Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for <i>In vivo</i> Efficacy under Intermittent Dosing Conditions
2023Open Access
Data from Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
2023Open Access
Data from Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
2023Open Access
Supplementary Figures 1-2 from Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
2023Open Access
Supplementary Figure Legends 1-2 from Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
2023Open Access
Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms
Anticancer Research·2018· 33 cited
46 Broad-spectrum preclinical combination activity of eribulin combined with various anticancer agents in human breast cancer, lung cancer, ovarian cancer, and melanoma xenograft models
European Journal of Cancer·2014· 1 cited
Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
PubMed·2012· 45 cited
Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
Cancer Research·2011· 93 citedOpen Access
Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility
Bioorganic & Medicinal Chemistry Letters·2011· 23 cited
Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model
Bioorganic & Medicinal Chemistry Letters·2011· 24 cited
page 1 of 3Next →

Frequent Co-authors

Bruce A. Littlefield(34), Melvin J. Yu(13), Boris M. Seletsky(12), K. Nomoto(12), Galina Kuznetsov(10), Yoshito Kishi(10), Karen TenDyke(10), Kathleen A. Salvato(9), Rena G. Lapidus(9), Kazuhiro Hayakawa(9), Satoru Hosokawa(9), Barbara S. Slusher(9), Bruce F. Wels(8), Kimberley K. Aalfs(8), Bryan M. Lewis(8), Krystyna M. Wozniak(8), Valentina Carozzi(8), Guido Cavaletti(8), Hongsheng Cheng(7), Junke Liu(7)